What is the current stock price of Carisma Therapeutics, Inc. (CARM)?

As of the latest market data, Carisma Therapeutics, Inc. (CARM) is trading at $0.03. The stock has seen a gain of 9.68% today.

Does Carisma Therapeutics, Inc. (CARM) pay a dividend?

Based on current data, Carisma Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Carisma Therapeutics, Inc.?

The current market capitalization of Carisma Therapeutics, Inc. (CARM) is approximately unavailable.

CARM

Carisma Therapeutics, Inc.·Healthcare

0.03

9.677%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0352W H: $1.27

CARM NEWS

businesswire.com

Feb 18

Carmila: 2025 Annual Results

PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): Three growth engines: NRI up 8.8% to €403.1 million Organic growth: adding 3.5% to net rental income, outpacing indexation by 110 basis points. Investment growth: adding 5.3% to net rental income; successful integration of Galimmo Innovation growth: recurring earnings contribution of €27 million, growing by 14% Operational excellence confirmed, all KPIs on an upward trend High financial occupancy rate: up 30 basis points to 96.5% Re.

defenseworld.net

Feb 5

Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM)

Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 14.0% of Context

Company Profile

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2014-02-06

Beta

3.50

Websitecarismatx.com↗